Mirogabalin

• CAT Number: I000523
• CAS Number: 1138245-13-2
• Molecular Formula: C12H19NO2
• Molecular Weight: 209.3
• Purity: ≥95%
• Synonyms: DS-5565
• Target: α2δ-1[1]
• Solubility: 10 mM in DMSO, Methanol: ≥ 35 mg/mL
• Storage: -20°C
• IUPAC Name: 2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid
• InChI: InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
• InChIKey: FTBQORVNHOIASH-CKYFFXLPSA-N
• SMILES: CCC1=CC2C(C1)CC2(CC(=O)O)CN

Mirogabalin (CAT: I000523) is a medication that belongs to the class of gabapentinoids, which are used for the management of neuropathic pain. It acts as a selective ligand for the α2δ subunit of voltage-gated calcium channels in the central nervous system, reducing the release of certain neurotransmitters involved in pain transmission. Mirogabalin has demonstrated efficacy in the treatment of various types of neuropathic pain, including diabetic peripheral neuropathy and postherpetic neuralgia. It offers an alternative treatment option for individuals who may not adequately respond to or tolerate other medications commonly used for neuropathic pain relief.

Reference

1. Vinik A, et al. Efficacy and safety of Mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.
2. Hutmacher MM, et al. Exposure-response modeling of average daily pain score, and dizziness and somnolence, forMirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. J Clin Pharmacol. 2016 Jan;56(1):67-77.